CVRx® & DaVita Announce Strategic Partnership

                CVRx® & DaVita Announce Strategic Partnership

PR Newswire

MINNEAPOLIS, Nov. 5, 2013

MINNEAPOLIS, Nov. 5, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device
company, and DaVita^®, a division of DaVita HealthCare Partners Inc, have
embarked on a strategic partnership. This partnership was established in
conjunction with CVRx's Series F $42 million financing in which DaVita
HealthCare Partners Inc. was recently added as a new investor. Under the
partnership, the two companies will collaborate on commercial activities and
clinical research intended to make CVRx's Barostim Therapy™ available to new
patient populations.

"We're delighted to welcome DaVita into our investor syndicate and are excited
to work together with DaVita and its affiliate, DaVita Clinical Research^®, a
specialty contract research organization with deep scientific and operational
experience in renal disease trials," said Robert Kieval, Founder and Chief
Technology Officer of CVRx."Given their demonstrated commitment to medical
innovation and advancing patient care, we are proud to have DaVita as a
partner as we continue forward."

"Our focus is to collaborate on innovative approaches to addressing the
complex clinical problems of patients with kidney disease to improve the
quality of their lives," said Allen R.Nissenson, MD FACP, Chief Medical
Officer for DaVita. "We believe the Barostim platform meets those criteria and
therefore has the potential to provide both meaningful clinical benefits to
patients and economic benefits to the health care system."

About DaVita
DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune
500^® company that, through its operating divisions, provides a variety of
health care services to patient populations throughout the United States and
abroad. A leading provider of kidney care in the United States, DaVita
delivers dialysis services to patients with chronic kidney failure and end
stage renal disease. DaVita strives to improve patients' quality of life by
innovating clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services. As of June
30, 2013, DaVita operated or provided administrative services at 2,010
outpatient dialysis centers located in the United States serving approximately
159,000 patients. The company also operated 48 outpatient dialysis centers
located in ten countries outside the United States. DaVita supports numerous
programs dedicated to creating positive, sustainable change in communities
around the world. The company's leadership development initiatives and social
responsibility efforts have been recognized by Fortune, Modern Healthcare,
Newsweek and WorldBlu. For more information, please visit DaVita.com.

About CVRx, Inc.
CVRx, Inc. is a privately-held company founded in 2001 and is headquartered in
Minneapolis. The company has developed the second generation Barostim neo™, an
implantable system designed to treat hypertension (high blood pressure) and
heart failure. In Europe, Barostim neo  received CE marking for the treatment
of hypertension and is in clinical evaluation for the treatment of heart
failure. In the United States Barostim neo  is in clinical evaluation for the
treatment of heart failure and hypertension. For more information, visit
Cvrx.com.

About Barostim neo
Barostim neo is a second generation device that uses CVRx-patented technology
that is designed to trigger the body's own natural blood flow regulation
system to treat hypertension and heart failure. The system works by
electrically activating the baroreceptors, the body's natural blood pressure
sensors that regulate cardiovascular function. These baroreceptors are located
on the carotid artery. When activated by Barostim neo, signals are sent
through neural pathways to the brain, which responds by telling the:

  oArteries to relax, making it easier for blood to flow through the body and
    reducing cardiac exertion;
  oHeart to slow down, allowing more time for the organ to fill with blood;
    and
  oKidneys to reduce fluid in the body, lowering both excessive blood
    pressure and workload on the heart.

This unique, patented technology has the potential to improve quality of life
and reduce health risks associated with hypertension and heart failure,
including heart and kidney disease, stroke and death. Other key potential
benefits of Barostim neo  include the following:

  oCan be adjusted to meet each patient's individual therapy needs, making it
    the only personalized medical device therapy for the treatment of
    hypertension with a CE marking;
  oIs a non-destructive reversible treatment; and
  oProvides 100% compliance to treatment, by automatically and continuously
    activating the baroreflex.

CAUTION: Barostim neo is an investigational device and is limited by United
States law to investigational use.

CVRx, Barostim Therapy and Barostim neo  are trademarks of CVRx, Inc.
registered in the United States Trademark Office.

DaVita and DaVita HealthCare Partners are trademarks or registered trademarks
of DaVita HealthCare Partners Inc.

© CVRx, Inc. 2013. All rights reserved.

SOURCE CVRx, Inc.

Website: http://www.cvrx.com
Contact: John Brintnall, Chief Financial Officer, jbrintnall@cvrx.com, Phone:
763.416.2853; Rebecca Olson, Corporate Communications, rolson@cvrx.com, Phone:
763.416.2355